Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

Fatty liver disease that develops in the absence of alcohol abuse is recognized increasingly as a major health burden. This report summarizes the presentations and discussions at a Single Topic Conference held September 20‐22, 2002, and sponsored by the American Association for the Study of Liver Diseases. The conference focused on fatty liver disorders. Estimates based on imaging and autopsy studies suggest that about 20% to 30% of adults in the United States and other Western countries have excess fat accumulation in the liver. About 10% of these individuals, or fully 2% to 3% of adults, are estimated to meet current diagnostic criteria for nonalcoholic steatohepatitis (NASH). Sustained liver injury leads to progressive fibrosis and cirrhosis in a fraction, possibly up to one third, of those with NASH, and NASH may be a cause of cryptogenic cirrhosis. NASH is now a significant health issue for obese children as well, leading to cirrhosis in some. The diagnostic criteria for NASH continue to evolve and rely on the histologic findings of steatosis, hepatocellular injury (ballooning, Mallory bodies), and the pattern of fibrosis. Generally recognized indications for biopsy include establishing the diagnosis and staging of the injury, but strict guidelines do not exist. Liver enzymes are insensitive and cannot be used reliably to confirm the diagnosis or stage the extent of fibrosis. Older age, obesity, and diabetes are predictive of fibrosis. The pathogenesis of NASH is multifactorial. Insulin resistance may be an important factor in the accumulation of hepatocellular fat, whereas excess intracellular fatty acids, oxidant stress, adenosine triphosphate (ATP) depletion, and mitochondrial dysfunction may be important causes of hepatocellular injury in the steatotic liver. Efforts are underway to refine the role of insulin resistance in NASH and determine whether improving insulin sensitivity pharmacologically is an effective treatment. An altered lifestyle may be a more effective means of improving insulin sensitivity. The research agenda for the future includes establishing the role of insulin resistance and abnormal lipoprotein metabolism in NASH, determining the pathogenesis of cellular injury, defining predisposing genetic abnormalities, identifying better noninvasive predictors of disease, and defining effective therapy.

[1]  A. Nanji,et al.  Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. , 1986, Enzyme.

[2]  R. Fisher,et al.  Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  H. Gin,et al.  Maternally Inherited Diabetes and Deafness: A Multicenter Study , 2001, Annals of Internal Medicine.

[4]  S. Collins,et al.  Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. , 1997, Biochemical and biophysical research communications.

[5]  Marco Zoli,et al.  Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.

[6]  P. Giral,et al.  Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis , 2002, Hepatology.

[7]  K. Petersen,et al.  Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. , 2002, The Journal of clinical investigation.

[8]  F. Marumo,et al.  Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. , 1997, Journal of clinical gastroenterology.

[9]  R. Paraná,et al.  Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. , 1999, Liver.

[10]  J. Kinsella,et al.  Effect of different dietary triglycerides on liver fatty acids and prostaglandin synthesis by mouse peritoneal cells. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[11]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[12]  N. Alshak,et al.  Dietary lecithin, antioxidant and vitamin B complex (LAB) decrease hepatic steatosis on patients with nonalcoholic steatoheaptitis (NASH) , 1998 .

[13]  M. Fernández-Bermejo,et al.  A wider view on diagnostic criteria of nonalcoholic steatohepatitis. , 2002, Gastroenterology.

[14]  R. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[15]  R. Lobo,et al.  The Importance of Diagnosing the Polycystic Ovary Syndrome , 2000, Annals of Internal Medicine.

[16]  A. Lonardo,et al.  Apolipoprotein synthesis in nonalcoholic steatohepatitis , 2002, Hepatology.

[17]  R. Mortimer,et al.  Steatohepatitis associated with limb lipodystrophy. , 1989, Gastroenterology.

[18]  R. Varma,et al.  Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[20]  R. Batey,et al.  Computer Assisted Quantitation of Terminal Hepatic Vein Connective Tissue in the Rat , 1992, Pathology.

[21]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[22]  R. Chamuleau,et al.  The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. , 1997, Journal of hepatology.

[23]  A. Dulloo Biomedicine. A sympathetic defense against obesity. , 2002, Science.

[24]  W. Kraus,et al.  Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[25]  T. Ben-Menachem,et al.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients , 1999, American Journal of Gastroenterology.

[26]  W. Kim,et al.  Recurrence of nonalcoholic steatohepatitis following liver transplantation. , 1996, Transplantation.

[27]  L. N. Valenti,et al.  Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[28]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[29]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[30]  T. Therneau,et al.  An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities , 2000, American Journal of Gastroenterology.

[31]  A Tremblay,et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. , 1994, The American journal of cardiology.

[32]  R. Ross,et al.  Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. , 2000, Journal of applied physiology.

[33]  J. Lehmann,et al.  Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. , 1997, Biochemical pharmacology.

[34]  Rahul Krishnarao Patil,et al.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.

[35]  S. Lu,et al.  Methionine adenosyltransferase and liver disease: it's all about SAM. , 1998, Gastroenterology.

[36]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[37]  W. Dietz,et al.  Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. , 2000, The Journal of pediatrics.

[38]  D. Jakubowicz,et al.  Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[39]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[40]  K. Lindor,et al.  Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study , 2001, American Journal of Gastroenterology.

[41]  O. Weiland,et al.  Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. , 2002, Journal of hepatology.

[42]  J. Flier,et al.  Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. , 1997, Endocrinology.

[43]  J. Patrie,et al.  Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.

[44]  H. Appelman,et al.  Regression of hepatic steatosis in morbidly obese persons after gastric bypass. , 1995, American journal of clinical pathology.

[45]  A. J. Mcadams,et al.  Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis. , 1974, Gastroenterology.

[46]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[47]  S. Caldwell,et al.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.

[48]  S. Thung,et al.  Hepatic Weber-Christian disease. , 2001, Seminars in liver disease.

[49]  J. K. Lee,et al.  Role of Hyperinsulinemia and Glucose Intolerance in the Pathogenesis of Nonalcoholic Fatty Liver in Patients with Normal Body Weight , 1998, The Korean journal of internal medicine.

[50]  I. Leclercq,et al.  Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[51]  W. van Steenbergen,et al.  Liver disturbances in obesity and diabetes mellitus. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[52]  G. Minuk,et al.  Clinical hepatology: Profile of an urban, hospital‐based practic , 1996, Hepatology.

[53]  H. Cortez‐Pinto,et al.  Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.

[54]  E. Drenick,et al.  Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. , 1970, The New England journal of medicine.

[55]  A. Dulloo A Sympathetic Defense Against Obesity , 2002, Science.

[56]  N. Kaplowitz,et al.  Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol‐treated rats: Effect of membrane physical properties and S‐adenosyl‐L‐methionine , 1997, Hepatology.

[57]  N. Barzilai,et al.  Leptin selectively decreases visceral adiposity and enhances insulin action. , 1997, The Journal of clinical investigation.

[58]  T. Saibara,et al.  Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. , 1999, Lancet.

[59]  I. Wanless,et al.  Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.

[60]  H Hoppeler Skeletal muscle substrate metabolism , 1999, International Journal of Obesity.

[61]  A. Czaja Recurrence of nonalcoholic steatohepatitis after liver transplantation. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[62]  Mark A Pereira,et al.  A low-glycemic index diet in the treatment of pediatric obesity. , 2000, Archives of pediatrics & adolescent medicine.

[63]  P. Ward,et al.  Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.

[64]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[65]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[66]  M. Dianzani Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. , 1954, Biochimica et biophysica acta.

[67]  C. García-Monzón,et al.  Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. , 2000, Journal of hepatology.

[68]  M. Washington,et al.  Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[69]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[70]  C. Gluud,et al.  Liver morphology in morbid obesity: a literature study. , 1984, International journal of obesity.

[71]  H. Cortez‐Pinto,et al.  Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.

[72]  J. Grove,et al.  Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis , 1997, Hepatology.

[73]  T. Wadden,et al.  AGA technical review on obesity. , 2002, Gastroenterology.

[74]  J. Romijn,et al.  Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. , 2001, Journal of hepatology.

[75]  F. Trevisani,et al.  Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status , 2001, Hepatology.

[76]  J. Goldstein,et al.  Liver histology abnormalities in the morbidly obese , 1989, Hepatology.

[77]  H. Zimmerman,et al.  Liver morphology and function tests in obesity and during total starvation , 1967, The American Journal of Digestive Diseases.

[78]  J. Kolanowski A Risk-Benefit Assessment of Anti-Obesity Drugs , 1999, Drug safety.

[79]  A. J. Bourne,et al.  Non‐alcoholic steatohepatitis in children and adolescents , 2000, The Medical journal of Australia.

[80]  G. Farrell Drugs and Steatohepatitis , 2002, Seminars in liver disease.

[81]  C. Mulrow,et al.  Does Counseling by Clinicians Improve Physical Activity? A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[82]  A. Nanji,et al.  Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. , 2001, The Journal of pharmacology and experimental therapeutics.

[83]  E. Roberts,et al.  Nonalcoholic steatohepatitis in children , 2003, Current gastroenterology reports.

[84]  M. Ishizaki,et al.  Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. , 1995, Journal of human hypertension.

[85]  C. Day CD14 promoter polymorphism associated with risk of NASH , 2002 .

[86]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[87]  M. Matsuda,et al.  Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. , 2002, Diabetes.

[88]  Shelly C. Lu,et al.  Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[89]  K. Ishak,et al.  Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. , 1988, Gastroenterology.

[90]  N. Ackerman Protein supplementation in the management of degenerating liver function after jejunoileal bypass. , 1979, Surgery, gynecology & obstetrics.

[91]  A. Nanji,et al.  Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. , 1995, Gastroenterology.

[92]  L. Teichholz Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[93]  D. M. Rocha,et al.  Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. , 1999, Diabetes.

[94]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[95]  L. N. Valenti,et al.  Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease , 2002 .

[96]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[97]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[98]  F. Schaffner,et al.  Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.

[99]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[100]  H. Lebovitz,et al.  Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. , 1999, The Journal of clinical endocrinology and metabolism.

[101]  D Echeverria,et al.  Hepatic ultrasonic changes in workers exposed to perchloroethylene. , 1995, Occupational and environmental medicine.

[102]  H. Bonkovsky,et al.  Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[103]  E. Keeffe,et al.  Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. , 1987, Digestive diseases and sciences.

[104]  J. Vamecq,et al.  Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.

[105]  E. Mun,et al.  Current status of medical and surgical therapy for obesity. , 2001, Gastroenterology.

[106]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[107]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[108]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[109]  S. Caldwell,et al.  Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease , 1999, Hepatology.

[110]  S. Strom,et al.  Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[111]  C. Gluud,et al.  Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.

[112]  M. Cullen,et al.  Nonalcoholic Steatohepatitis , 1997, Annals of Internal Medicine.

[113]  A. Tabares,et al.  Adaptation to a fish oil diet before inducing sepsis in rats prevents fatty infiltration of the liver. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[114]  G. Farrell,et al.  Etiopathogenesis of Nonalcoholic Steatohepatitis , 2001, Seminars in liver disease.

[115]  C. Gluud,et al.  The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. , 1984, International journal of obesity.

[116]  P. Moulin,et al.  Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes , 2000, Diabetologia.

[117]  S. Caldwell,et al.  Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis , 2005, Hepatology.

[118]  N. Jones,et al.  Exercise limitation in health and disease. , 2000, The New England journal of medicine.

[119]  M. Camilo,et al.  Tamoxifen-associated steatohepatitis--report of three cases. , 1995, Journal of hepatology.

[120]  Ackerman Nb Protein supplementation in the management of degenerating liver function after jejunoileal bypass. , 1979 .

[121]  M. Yamagata,et al.  Role of eicosapentaenoic acid in lipid metabolism in the liver, with special reference to experimental fatty liver. , 1994, Clinical therapeutics.

[122]  P. Harrigan,et al.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.

[123]  J. Antosiewicz,et al.  Suppression of the hydrazine-induced formation of megamitochondria in the rat liver by alpha-tocopherol. , 1994, Experimental and molecular pathology.

[124]  B. Vessby Dietary fat and insulin action in humans , 2000, British Journal of Nutrition.

[125]  C. van den Branden,et al.  Alterations of peroxisomes in steatosis of the human liver: A quantitative study , 1995, Hepatology.

[126]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[127]  R. Villa,et al.  Pharmacology of lazaroids and brain energy metabolism: a review. , 1997, Pharmacological reviews.

[128]  E. Schiff,et al.  The Use of piogliatazone in menalcoholic stealohepatitis , 2001 .

[129]  M. Başaranoǧlu,et al.  A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. , 1999, Journal of hepatology.

[130]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.

[131]  W. Vogel,et al.  Prognosis and life expectancy in chronic liver disease , 1995, Digestive Diseases and Sciences.

[132]  Nash Crn Nonalcoholic steatohepatitis clinical research network , 2003, Hepatology.

[133]  R. Hammer,et al.  Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. , 1996, The Journal of clinical investigation.

[134]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler , 1995, Hepatology.

[135]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[136]  A. Saltiel New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes , 2001, Cell.

[137]  M. Baak Exercise training and substrate utilisation in obesity , 1999, International Journal of Obesity.

[138]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[139]  S. Caldwell,et al.  Subacute liver failure in obese women , 2002, American Journal of Gastroenterology.

[140]  A. Franzese,et al.  Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. , 2000, The Journal of pediatrics.

[141]  T. Crabtree,et al.  Hepatitis C–induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate , 2000, Hepatology.

[142]  S. Caldwell,et al.  A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.

[143]  J. Friedman,et al.  Selective deletion of leptin receptor in neurons leads to obesity. , 2001, The Journal of clinical investigation.

[144]  F. Santorelli,et al.  Uncoupling protein-1 mRNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. , 2000, Biochemical and biophysical research communications.

[145]  E. Fisher,et al.  Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.

[146]  D. Pessayre,et al.  Mitochondria in Steatohepatitis , 2001, Seminars in liver disease.

[147]  A. Terano,et al.  Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.

[148]  G. Shulman,et al.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[149]  P. Armstrong,et al.  Amiodarone hepatotoxicity simulating alcoholic liver disease. , 1984, The New England journal of medicine.

[150]  J. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[151]  B. Teusink,et al.  Mice Expressing Only the Mutant APOE3Leiden Gene Show Impaired VLDL Secretion , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[152]  A. Scheen,et al.  Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty , 1998, International Journal of Obesity.

[153]  R. Swerdlow,et al.  Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. , 1998, Biochemical and biophysical research communications.

[154]  R. Haggitt,et al.  Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. , 1980, Gastroenterology.

[155]  Q. Cai,et al.  Tamoxifen-induced transient multifocal hepatic fatty infiltration , 2000, American Journal of Gastroenterology.

[156]  A. Diehl,et al.  Animal Models of Steatosis , 2001, Seminars in liver disease.

[157]  P. Vajro,et al.  Persistent hyperaminotransferasemia resolving after weight reduction in obese children. , 1994, The Journal of pediatrics.

[158]  F. Brancati,et al.  Nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[159]  D. Helinski,et al.  A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients , 2004, Alimentary pharmacology & therapeutics.

[160]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[161]  J. Silverman,et al.  Liver pathology in morbidly obese patients with and without diabetes. , 1990, The American journal of gastroenterology.

[162]  J. Silverman,et al.  Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. , 1989, Pathology annual.

[163]  J. Björkegren,et al.  A Deficiency of Microsomal Triglyceride Transfer Protein Reduces Apolipoprotein B Secretion* , 2000, The Journal of Biological Chemistry.

[164]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[165]  N. Chavez-Tapia,et al.  Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. , 2004, Annals of hepatology.

[166]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[167]  S. Gregory,et al.  LMNA, encoding lamin A/C, is mutated in partial lipodystrophy , 2000, Nature Genetics.

[168]  M. Rosen,et al.  Imaging of Hepatic Steatosis , 2001, Seminars in liver disease.

[169]  R. Stoohs,et al.  Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[170]  U. Akarca,et al.  Treatment of non-alcoholic steatohepatitis with N-acetyl cystein , 2000 .

[171]  E. Drenick,et al.  Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. , 1982, Gastroenterology.

[172]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[173]  Y. Takei,et al.  Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.

[174]  R G Shulman,et al.  Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. , 1991, Science.

[175]  H. Shimano,et al.  Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance inLep ob /Lep ob Mice* , 2002, The Journal of Biological Chemistry.

[176]  J. Björkegren,et al.  Blocking the Secretion of Hepatic Very Low Density Lipoproteins Renders the Liver More Susceptible to Toxin-induced Injury* , 2002, The Journal of Biological Chemistry.

[177]  Z. Younossi,et al.  Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[178]  H. Nittono,et al.  Effect of taurine on the fatty liver of children with simple obesity. , 1996, Advances in experimental medicine and biology.

[179]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[180]  O. Cummings,et al.  Atorvastatin for the treatment of NASH , 2001 .

[181]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[182]  B. Bacon,et al.  Hepatic iron and nonalcoholic fatty liver disease , 1999, Hepatology.

[183]  T. Saibara,et al.  Bezafibrate for tamoxifeninduced non-alcoholic steatohepatitis , 1999, The Lancet.

[184]  E. Schiff,et al.  Prevalence of nonalcoholic steatohepalitis among ethnic groups , 2001 .

[185]  R. Kuczmarski Need for body composition information in elderly subjects. , 1989, The American journal of clinical nutrition.

[186]  J. Colombel,et al.  Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure. , 1996, The American journal of gastroenterology.

[187]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[188]  P. Scheuer,et al.  Does a linear pattern of sinusoidal IgA deposition distinguish between alcoholic and diabetic liver disease? , 2008, Liver.

[189]  K. Eriksson,et al.  Nonalcoholic steatohepatitis in obesity: a reversible condition. , 2009, Acta medica Scandinavica.

[190]  A. Frydén,et al.  The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. , 1999, Scandinavian journal of gastroenterology.

[191]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[192]  A. West,et al.  Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. , 1990, Gastroenterology.

[193]  D. Alvaro,et al.  Effect of S-adenosyl-L-methionine on ethanol cholestasis and hepatotoxicity in isolated perfused rat liver. , 1995, Digestive diseases and sciences.

[194]  G. Loss,et al.  Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.

[195]  H. Cortez‐Pinto,et al.  Non-alcoholic fatty liver: another feature of the metabolic syndrome? , 1999, Clinical nutrition.

[196]  P. Christoffersen,et al.  Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material. , 2009, Acta medica Scandinavica.

[197]  P. Wang,et al.  Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by macrophages via H2-receptors. , 2001, International immunopharmacology.

[198]  M. Perola,et al.  Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease , 2001, Hepatology.

[199]  A. Sasaki,et al.  Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. , 1989, Diabetes research and clinical practice.

[200]  N. Davidson,et al.  APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. , 2000, Annual review of nutrition.

[201]  P. Christoffersen,et al.  Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. , 1977, Scandinavian journal of gastroenterology.

[202]  G. Pacini,et al.  Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.

[203]  B. Lowell,et al.  βAR Signaling Required for Diet-Induced Thermogenesis and Obesity Resistance , 2002, Science.

[204]  A. Garg,et al.  Editorial: Hepatic steatosis, insulin resistance, and adipose tissue disorders , 2002 .

[205]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[206]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[207]  B. Koneru,et al.  Oxidative stress in fatty livers of obese Zucker rats: Rapid amelioration and improved tolerance to warm ischemia with tocopherol , 2001, Hepatology.

[208]  S. Friedman,et al.  Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice , 2002, Hepatology.

[209]  B. Lowell,et al.  Obesity‐related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2 , 2002, Hepatology.

[210]  R. Stewart,et al.  Weight loss in obese women--exercise v. dietary education. , 1990, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[211]  S. Malnick,et al.  Fatty liver--an additional and treatable feature of the insulin resistance syndrome. , 1999, QJM : monthly journal of the Association of Physicians.

[212]  J. Parks,et al.  Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.

[213]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[214]  F. Brunetti,et al.  Liver Involvement in Obese Children (Ultrasonography and Liver Enzyme Levels at Diagnosis and During Follow-up in an Italian Population) , 1997, Digestive Diseases and Sciences.

[215]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[216]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[217]  T. Peters,et al.  Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. , 1983, Clinical science.

[218]  P. Scheuer,et al.  Liver Damage due to Methotrexate in Patients with Psoriasis , 1971, British medical journal.

[219]  D. Pessayre,et al.  Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. , 1997, Gastroenterology.

[220]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[221]  F. Kuhajda,et al.  Metformin reverses fatty liver disease in obese, leptin-deficient mice , 2000, Nature Medicine.

[222]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[223]  Z. Younossi,et al.  Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? , 2002, Gastroenterology.

[224]  A. Bowcock,et al.  AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.

[225]  C. Degott,et al.  Liver in obesity. , 1985, Gut.

[226]  M. Arrese,et al.  Evidence of intestinal bacterial overgrowth in patients with non-alcoholic steato-hepatitis , 2001 .

[227]  A. Garg,et al.  A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .

[228]  M. Dianzani The content of adenosine polyphosphates in fatty livers. , 1957, The Biochemical journal.

[229]  J. H. Johnson,et al.  Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[230]  Harbans Singh,et al.  High prevalence of NASH among Mexican American females with type II diabetes mellitus , 2001 .